|Dr. Jason Scott Slakter M.D.||Chief Exec. Officer, Pres and Director||375.19k||N/A||59|
|Mr. Samuel Backenroth||Chief Financial Officer and VP of Bus. Devel.||324.12k||N/A||33|
|Dr. Avner Ingerman M.D.||Chief Clinical Officer||381.24k||N/A||53|
|Dr. Glenn L. Stoller M.D.||Chief Scientific Officer||N/A||N/A||53|
|Dr. Peter K. Kaiser M.D.||Head of Product Devel.||N/A||N/A||N/A|
OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.
Ohr Pharmaceutical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.